How to Create and Grow a Successful Biotechnology Cluster

www.gate2biotech.cz • www.hospimedica.cz

How to Create and Grow a Successful Biotechnology Cluster 22. October 2008 • Brno, Czech Republic 3rd International Biotechnology Conference Gate2Biotech • How to Create and Grow a Successful Biotechnology Cluster

1

Welcome address The Czech Republic does not have any big deposits of raw materials, and it has big problems maintaining a clean environment. For that reason, all high-tech technologies that make no big demands on raw materials or energy, and, at the same time, do not produce significant amounts of waste are ideal for the Czech Republic. Modern biotechnologies, and cellular and gene engineering in particular, meet those criteria. It therefore comes as no surprise that biotechnologies have for many years been among topics at the top on the priority list for public funding. Such topics do not include only basic research projects in such fields as molecular genetics, immunology and others, but, especially, projects closely linked to a practical implementation. While basic – and oftentimes even applied – research is well established at Czech universities and in institutes of the Academy of Sciences of the Czech Republic and is of high quality, the number of new themes for production in existing undertakings, or for the establishment of new undertakings, remains insufficient. This is then reflected in the small number of biotechnology companies and in unsatisfactory numbers of employees in this field, and in a low turnover in general. We are now facing a big challenge for the development of biotechnologies in the Czech Republic, which is the implementation of the Operational Programme Research and Development for Innovations (OP RDI). A number of institutions in the main biotechnology centres in Brno, Olomouc and in the Central Bohemian region near Prague have joined forces to work on projects that may substantially boost the development of applied biotechnologies. Research and development in biotechnology companies should be further promoted by the Operational Programme Enterprise and Innovations (OP EI), which is coordinated by the Ministry of Industry and Trade of the Czech Republic. We believe that all these programmes will substantially contribute to the establishment of new infrastructures and will increase the volume of research, development and implementation of biotechnology products in the Czech Republic.

Doc. MUDr. Vladimír Viklický, CSc. Director of the Radiopharmaceuticals Division of the Nuclear Research Institute Řež plc

3rd International Biotechnology Conference Gate2Biotech • How to Create and Grow a Successful Biotechnology Cluster

3

Gate2Biotech Conference Programme 09:00–10:00

Registration & Coffee

Moderator:

Jiří Krechl, Ph.D., Director of R&D Support Department, CzechInvest

SECTION 1:

Get Inspired by the Best Practices on Cluster Development from Abroad Welcome and Opening: Miloň Polešák, Executive Manager for SME Clients at ČSOB Mark S. Paller, M.D., M.S., Assistant Vice President for Research, Academic Health Center and Professor of Medicine at the University of Minnesota (Rochester, Minnesota, U.S.A.): Minnesota Partnership – Activities and Impact Eric D. Wieben, M.D., Ph.D., Director, Mayo Genomics Research Center, Mayo Clinic (Rochester, Minnesota, U.S.A.) & Co-Director, Minnesota Partnership for Biotechnology and Medical Genomics: Building Scientific Partnership in Biotech Research between Minnesota and Brno – Challenges and Needs 11:05–11:35 Dr. Jeff Solomon, CEO, ERBI (Eastern Region Biotech Initiative), Cambridge, UK: Cambridge and the East of England Biotech Cluster 11:35–12:05 Robert David Kirk, Senior Lecturer, Centre for Enterprise Management, University of Dundee, Scotland (UK): BioDundee 12:05–12:25 Questions & Discussion 12:25–13:30 Lunch & Discussion

10:00–10:05 10:05–10:35 10:35–11:05

SECTION 2:

Do the Key Czech Biotech Projects reflect the Global Trend? 13:30–13:35 13:35–13:55 13:55–14:15 14:15–14:35 14:35–14:55 14:55–15:55

Welcome and Opening Tomáš Kára, M.D., PhD., Medical Director, International Clinical Research Center Brno (ICRC Brno): ICRC Project Update Prof. Jaroslav Koča, Masaryk University Brno: Central European Institute of Technology(CEITEC) Project Update Peter Šebo, PhD., Director, Institute of Biotechnology AS CR, v.v.i.: BIOCEV Project Update Dr. Michal Kostka, South Moravian Innovation Centre: Results of Regional Survey on Trends in Life Sciences Questions & Discussion

Main Partner

Československá obchodní banka, a. s. Československa obchodni banka, a. s. is a universal bank operating in the Czech Republic. ČSOB was established by the state in 1964 as a bank to provide foreign trade financing and convertible currency operations. It was privatized in June 1999 when KBC Bank, a member of Belgium’s KBC Group, became the majority owner. ČSOB took over Investicní a Poštovní banka, a.s. in June 2000. ČSOB had been active in both Czech and Slovak markets until 2007; the Slovak branch was separated as of 1 January 2008. ČSOB’s business profile comprises the following segments: retail (individuals), SMEs, corporate and non-banking financial institutions, financial markets and private banking. ČSOB is operating under two retail brands in the Czech Republic – ČSOB and Poštovní spořitelna (Postal Savings Bank – PSB); the latter is using the wide distribution network of Czech Post. To serve their clients, ČSOB has 227 branches in the Czech Republic while PSB has 32 Financial Centers and approx. 3,350 post offices (as at 30 June 2008). Both ČSOB and PSB also provide their services through various direct-banking channels. In addition to its own products, ČSOB is distributing products and services of the whole ČSOB Group. Along with its own products and services, ČSOB’s branch network offers products and services of the entire ČSOB Group. Comprehensive service portfolio thus also includes insurance and pension products (ČSOB Pojišťovna and the Stabilita and Progres pension funds), financing the housing needs (Hypotečni banka and Českomoravská stavební spořitelna) collective investment and asset management (investment funds of ČSOB Investment company a ČSOB Asset Management) and specialized services (ČSOB Leasing and ČSOB Factoring). Services related to trading on financial markets are provided by Patria, a sister company of ČSOB. The primary goal of the ČSOB Group is to build a strong, long-term partnership with each client by being a good listener and offering suitable solutions, not just products, and providing clients with livelong advisory services in the areas of personal and family needs, SME and corporate finance.


5

Enterprise Europe Network

“A one-stop shop for businesses in over 40 countries” The Enterprise Europe Network is the largest network of contact points providing information and advice to EU companies on EU matters, in particular small and medium enterprises (SMEs). The network offers concrete and effective solutions to entrepreneurs and companies in more than 40 countries, including the 27 EU member states, three EU candidate countries (Croatia, the former Yugoslav Republic of Macedonia and Turkey), members of the European Economic Area (EEA) and other participating third countries. Launched in 2008 by the European Commission, the Enterprise Europe Network combines and builds on the former Innovation Relay Centres and Euro Info Centres (established in 1995 and 1987 respectively). The new integrated network offers a “one-stop shop” to meet all the information needs of SMEs and companies in Europe. Instruments include business partner search within technology and business cooperation databases and fast access to information on funding opportunities, individual on-site visits to companies to assess their needs and a broad range of promotion and information material. Representatives of the network can also help businesses understand EU law, how it applies to their business and how to make the most the internal market and EU programmes. The Enterprise Europe Network fully exploits the synergies between all support services and helpdesks aimed at European businesses. The “one-stop shop” service is accompanied by a “no wrong door” policy: an entrepreneur or business actor can enter the network through any contact point, and will then be assisted and personally directed to the relevant service or organisation. Business actors are encouraged to share, define and disseminate best practices in fields such as innovation, expansion to new markets, enlargement of the client base, improvement of market position, etc. As a result, the Enterprise Europe Network helps SMEs realise their potential in terms of growth and regional job creation. Activities of the Czech Enterprise Europe Network are realized by a consortium of eleven project partners coordinated by the Technology Centre of Academy of Sciences of the Czech Republic. www.enterprise-europe-network.cz

The project is supported by the Competitiveness and Innovation Framework Programme (CIP)

Speakers Index Mark S. Paller, M.D., M.S. Dr. Mark S. Paller is Assistant Vice President for Research, Academic Health Center and Professor of Medicine at the University of Minnesota. He oversees the Office of Clinical Research, the Biomedical Genomics Center, the Molecular and Cellular Therapy Program, Research Animal Resources, and all AHC intramural grant programs. He played a key role in developing the research partnership between the University of Minnesota and Mayo Clinic, the Minnesota Partnership for Biotechnology and Medical Genomics, which he co-directs. Nationally, he was the founding chair of the Association of Academic Health Centers Vice Presidents for Research Executive Leadership Group. Paller has extensive experience in basic and translational research with more than 100 publications. His primary research interest and area of expertise is the cell biology of acute renal failure. Paller received his medical degree at Northwestern University, performed an internal medicine residency at Case Western Reserve University and a nephrology fellowship at the University of Colorado, and received a Master’s degree in Administrative Medicine from the University of Wisconsin-Madison. He is a practicing nephrologist with interests in chronic kidney disease, transplantation, pregnancy and kidney disease, and hypertension.

Eric D. Wieben Dr. Wieben is the Director of Mayo Clinic Genomics Research Center and Professor of Biochemistry and Molecular Biology at the College of Medicine-Mayo Clinic. He is also on the Board of Directors of the BioBusiness Alliance of Minnesota. As the son of an Army officer, Eric grew up in many locations including France, Japan, and Senegal. He graduated from high school in Israel and began college at Tel Aviv University. Dr. Wieben earned a B.S. degree in Biological Sciences with highest distinction from Indiana University and a Ph.D. in Biology from Yale University. Dr. Wieben completed his post doctoral fellowship at the Worcester Foundation for Experimental Biology before joining the Department of Biochemistry and Molecular Biology at Mayo in 1983. Dr. Wieben was Chair of the department for 7 years during a time when the department was facing major challenges from the genomic revolution. In 2002 he became the Director of the Genomics Research Center at Mayo and in 2003 he helped to establish the Minnesota Partnership for Biotechnology and Medical Genomics, Mayo‘s public-private collaboration with the University of Minnesota and the State of Minnesota. Dr. Wieben’s current and primary research interest is in the area of pharmacogenomics. He is collaborating with Dr. Richard Weinshilboum to determine how genes influence the response of individuals to drug therapy. They are working to define the range of individual genetic variation in the genes that code for drug metabolizing enzymes, and how that variation can influence both the effectiveness of the drug and the likelihood of adverse side effects. 3rd International Biotechnology Conference Gate2Biotech • How to Create and Grow a Successful Biotechnology Cluster

7

Dr. Wieben has received many rewards and recognitions, including 5 patents and the Mayo Foundation Distinguished Educator Award.

Jeff Solomon Jeff graduated from University College London with a Ph.D. in biochemical engineering and has over 25 years experience working with a variety of organizations within the healthcare and life science sectors undertaking and managing R&D and developing strategy. He joined the ERBI initiative and focused its efforts on the development of networking and communications within the Cambridge and East of England biocommunity. In April 2000 ERBI became an independent not-for-profit company and Jeff became its full time Chief Executive. In that time ERBI has grown to over 360 paying members and ERBI has increased 10 fold in size. In January 2008 ERBI added activities aimed specifically at the medtech community. Jeff has worked in Cambridge for 25 years and has experienced the growth of biotechnology in the region. In his spare time, Jeff is a member of the Institute of Directors, an advisory board member for the Centre for Integrated Photonics (CIP), sits on the advisory panel for UKTI’s Biotechnology and Pharmaceutical Services and finally is the Chair of the Council of European Bioregions.

Robert David Kirk David Kirk is the director of Masters Degree programmes in Spatial Planning at the University of Dundee, Scotland. Upon graduating in 1972 from the University of Glasgow, David followed a professional career in programme planning and project management in a variety of public and private organisations in the UK, positions in which he was principally involved in economic development. In 1993, he began a university career and has led programmes in enterprise management and in spatial planning. David collaborated with a number of technical universities and industrial firms in Poland during the 1990’s for which he received the award of the Knights Cross from the Republic of Poland in 2002. He has a number of published papers on innovation and knowledge transfer. Over the last three years he was an active participant in the NetBioClue network sharing knowledge about the processes required for developing biotech clusters.

Tomáš Kára Tomáš Kára, MD, PhD is the Executive Director of the International Clinical Research Center Brno project that will be constructed at St. Anne’s Hospital in Brno, Czech Republic and Associate Professor of Medicine at Division of Cardiovascular Diseases at Mayo Clinic and Mayo School of Medicine, Rochester, Minnesota. Dr. Kara’s main focus is clinical cardiology and cardiovascular research, including development of new technologies for cardiovascular diseases diagnostics and treatment.

Arnošt Marks Arnost Marks (41) graduated from Charles University (Prague) with masters degree in general biology in 1991 later he received PhD. degree on Knowledge and Technology Management Transformation in Post Communist Countries from University of Cambridge in 1997. Then he worked for Technology Centre of the Czech Academy of Sciences and as a project manager he ran projects for technological companies on EU programmes. He spent 8 years in public administration working for Deputy Chairman of Senate, Advisor to the Ambassador of the EU in the Czech Republic and finally as a director general responsible for managing implementation EU Funds in the Czech Republic 2004–2006 and 2007–2013 in the Ministry for Regional Development. Presently he represents project of Central European Institute of Technology (CEITEC) in Brno as its executive director.

Peter Šebo Dr. Peter Šebo worked for 6 years at CNRS and Institut Pasteur in Paris, before he returned to the Institute of Microbiology in Prague in 1995. He is currently the director of the newly founded Institute of Biotechnology and is in charge of preparing the construction of a major research infrastructure for the Biotechnology Research Center of the Academy of Sciences with Charles University (BIOCEV).

Jiří Hudeček Jiří Hudeček is CEO of the South Moravian Innovation Centre, leading Czech organization for support of innovative start-up companies. As an entrepreneur and manager with over 10 years of experience in senior positions, Jiří has worked for a number of institutions including GE Capital Bank, LKW Walter International and others. He currently leads a team of 20 professionals dedicated to support of innovative enterprises in the South Moravian region through implementation of the Regional Innovation Strategy.


9

Internet portal www.gate2biotech.cz contains all information about biotechnology in one place. The website is aimed at biotechnology companies, suppliers, investors, institutions, students, professional community and everyone interested in this field of future. Gate2Biotech maps over all biotech news and its users can also find a complete database of Czech biotechnology companies and research entities. The database is searchable by their specialisation, offers and request of collaboration or jobs, overview of currently undertaken research projects, contains information on international conferences, seminars, fairs and other interesting events. Through the portal the companies can easily search partners for various technology problem solutions and present their services to potential partners from the Czech Republic and abroad. The users of the website are located in more than 50 countries.

Internet portal www.inovace.cz aims to create a central place for all Czech subjects interested in innovation by providing targeted information, linking to other relevant services and assisting in realisation of their innovative projects. The website is aimed at researchers, inventors, innovative companies, research institutions, investors and organisations supporting innovations. The content of the website comprises information on innovation from the Czech Republic and abroad providing:

Information about funding and support innovative projects Important contacts, supply and demand for cooperation News and articles about trends in research and development Calendar of events Case Studies

Organization

International Clinical Research Center Brno (ICRC) One of the European Union’s largest initiatives for the 21st century in the area of biotechnology and medical research will be based on collaboration between the Mayo Clinic and the Czech Republic’s International Clinical Research Center (lCRC) in Brno, Czech Republic. The ICRC partnership will focus on medical research and education, particularly in the areas of cardiovascular and neurovascular diseases, internal medicine, neurology and oncology. The multifunctional centre will offer advanced clinical research facilities, a state-of-the-art cardiovascular clinical centre, international educational centre and a technology cluster. ICRC brings to Czech scientists new opportunities for international collaboration. www.icrcbrno.org St. Anne’s University Hospital Pekařská 53 656 91 Brno Tomáš Kára, M.D., Ph.D. Executive Director, ICRC Brno Tel.: +420 543 181 161 E-mail: [email protected]


11

The South Moravian Innovation Centre The South Moravian Innovation Centre (JIC) creates a complex infrastructure for innovative enterprise in the South Moravian region supporting innovative companies, science, research and development and students with original ideas. JIC was established as an association of legal entities in 2003. Its founders are the South Moravian Regional authority, the Statutory City of Brno, Masaryk University and Brno University of Technology. In February 2005 the group was joined by Mendel University of Agriculture and Forestry and University of Veterinary and Pharmaceutical Sciences in Brno. The services of the Centre are based on four key pillars:

finances consultancy contacts premises

One of the main activities of the centre is operating the Technology Incubator at Brno University of Technology and the Technology Incubator II of the South Moravian Regional Authority, which concentrate several support tools for starting entrepreneurs in one place, reduce the risk for start-ups and assist them to achieve the level they could engage selfdependently in commercial-economic activities and compete on the market. The South Moravian Innovation Centre is the coordinator of the Regional Innovation Strategy of the South Moravian Region which is a strategy for increasing implementation and fostering innovation. JIC is a member of the Enterprise Europe Network – the largest network of contact points providing information and advice to EU companies on EU matters, in particular small and medium enterprises (SMEs). The South Moravian Innovation created and operates 2 web portals: www.INOVACE.cz aims to create a central place for all subjects interested in innovation by providing targeted information, linking to other relevant services and assisting in realisation of their innovative projects, portal www.gate2biotech.cz, is the main guide-post and information umbrella covering all biotech activities in the Czech Republic. In 2006 JIC published the first ever annual publication of detailed information about Czech biotech sector “Czech Biotech Report”. JIC, zajmove sdruzeni pravnickych osob U Vodárny 2 616 00 Brno Tel.: +420 541 143 000 Fax: +420 541 143 011 www: www.jic.cz E-mail: [email protected]

List of Participants 1

Adámek Petr, Ing. MBA

Berman Group – služby ekonomického rozvoje, s.r.o.

2

Bažant Petr, Ing. CSc. MBA

Ústav experimentální medicíny AV ČR, v.v.i.

3

Bernatová Karolína

Vysoká škola Báňská

4

Bohrn Tomáš

ChipInvest a.s.

5

Bryndová Marta, Ing.

MZLU v Brně

6

Bula Daniel

7

Bunček Martin, RNDr., Ph.D.

GENERI BIOTECH s.r.o.

8

Cieslarová Jaroslava, Mgr.

MZLU Brno

9

Činčarová Lenka, Mgr

Masarykova Univerzita, PřF

10

Damborský Jiří, Dr.

Enantis s.r.o.

11

Dita Ilona

Biotechnologický ústav AV ČR, v.v.i.

12

Doležalová Anna

Výzkumný ústav bramborářský Havlíčkův Brod, s.r.o.

13

Domkářová Jaroslava


14

Fryč Jan

VŠB – TU Ostrava

15

Fusek Martin, Doc. Ing. CSc.

Life Sciences Capital s.r.o.

16

Greplová Marie


17

Grochová Diana, PhD.

Centrum prenatální diagnostiky, s.r.o.

18

Guňka Karel, Ing.

CONSULT

19

Hadam Jakub, Mgr.

Merck, s.r.o.

20

Havlíček Martin, Ing.

Ústav biomedicínského inženýrství VUT v Brně

21

Havránek Ivo

VŠB – TU Ostrava

22

Hejátko Jan

Masarykova Univerzita

23

Heřmánek Jiří, RNDr.,MBA

Genzyme Europe BV

24

Hettner Michal

Central European Biosystems s.r.o.

25

Hezinová Věra, Ing.

Ústav analytické chemie AV ČR, v.v.i.

26

Holub Petr, Mgr.

NCBR – Národní centrum pro výzkum biomolekul

27

Horna Aleš, Doc. Ing. CSc.

RADANAL

28

Hradil Ondřej, Ing.

Masarykova univerzita

29

Hrdličková Barbara

UPF LF, Masarykova Univerzita

30

Hudzieczek Vojtěch

MZLU Brno

31

Hutňan Ivan, Ing.

BIOHEM s.r.o.

32

Hutová Eliška

VUT v Brně

33

Chaloupka Jaroslav, Ing., PhD.

BIC Brno, Podnikatelské a inovační centrum

34

Chalupová Pavla, Ing.

MZLU v Brně

35

Chládek Petr, Mgr.

Regionální rozvojová agentura jižní Moravy

36

Chrást Lukáš

Masarykova Univerzita – PřF

37

Chroboková Eva

Zahradnická fakulta MZLU v Brně

38

Chromá Ludmila, Ing. PhD.

Bioveta, a.s.

39

Chroustovský Jiří

Worthald Partners

40

Jablonka Radim

VŠB – TU Ostrava

41

Janouškovcová Eva, RNDr., Ph.D.


42

Jaroš Josef, Ing.


43

Kalivodová Tereza, Ing.

Brain Logistics, s.r.o.

44

Kaplanová Kateřina, Ing.

MZLU v Brně

45

Klečková Zita, PhDr.

CEET s.r.o.


13

46

Kolář Vladimír, RNDr.

BioVendor – Laboratorní medicína a.s.

47

Koudelka Štěpán, Ing.

Výzkumný ústav veterinárního lékařství

48

Kowalczuková Barbora

ICRC Brno

49

Kramářová Gabriela, Bc.

British Embassy

50

Krejčí Jan, RNDr., PhD.

BVT Technologies a.s.

51

Krupková Olga, Bc.

52

Křepelka Jiří, Ing., CSc.

INVENTIA s.r.o

53

Kubešová Barbara, MUDr.

Tkáňová banka FN Brno

54

Kubešová Blanka


55

Kupská Eva, Ing.

VOP-026 Šternberk, s.p., divize VTÚO Brno

56

Lapka Roman, RNDr.

Zentiva a.s.

57

Lexa Jiří, Ing.

Centrum ekonomických studií VŠEM

58

Libra Antonín, Ph.D.

GENERI BIOTECH s.r.o

59

Linhart Jakub

Bioveta, a.s.

60

Lukáč Róbert, Mgr.


61

Maděránková Denisa, Ing.

VUT v Brně, FEKT, ÚBMI

62

Makyčová Michaela, Mgr.

Teva Pharmaceuticals CR, s.r.o.

63

Marková Michaela, RNDr.

Biofyzikální ústav AV ČR, v.v.i.

64

Mašek Josef, Mgr.


65

Mikeš Jiří, Ing.

EPS s.r.o.

66

Moudra Alena, Bc.


67

Mozga Tomáš, Mgr.


68

Mráčková Martina

Biofyzikální ústav AV ČR, v.v.i.

69

Mrázek Stanislav, MBA

CEITEC Cluster

70

Nadiradze Kakha

Biotechnology Center of Georgia

71

Nicodemou Andreas, Mgr.

BIOHEM s.r.o.

72

Novotná Zlatuše, MVDr.


73

Obruča Stanislav, Ing.

Fakulta chemická VUT v brně

74

Opletal Kamil

Mitsubishi Corporation

75

Partl Martin, Ing.

CzechInvest

76

Passe Jana

Passe Intellectual Property, LLC

77

Passe Jim

Passe Intellectual Property, LLC

78

Pavlík Adam

79

Petřík Theodor, Ing., CSc.

Shimadzu GmbH organizační složka

80

Pisko Michal, Ing., Ph.D.

ExPS s.r.o.

81

Pitthart Tomáš

Institut klinické a experimentální medicíny

82

Plchút Martin, Ing.

ANF Data

83

Plucar Bohumír, MUDr.

4 RESEARCH s.r.o.

84

Polzerová Hana


85

Proksa Bohumil, Ing. DrSc.

Zentiva a.s.

86

Prokšík Jan, Ing.

Ústav experimentální medicíny AV ČR, v.v.i.

87

Průchová Anna


88

Rajnoch Jan, MUDr.

Biotechnologický ústav AV ČR, v.v.i.

89

Rašková Petra, Ing.

Jihočeská agentura pro podporu inovačního podnikání o.p.s.

90

Rohrer Michal

MZLU v Brně

91

Roleček Jiří, Ing.


92

Rusek Jakub, Bc.

Masarykova Univerzita – PřF

93

Ružovič Tomáš

VŠB – TU Ostrava

94

Sára Petr, Mgr.

Pliva – Lachema Diagnostika s.r.o.

95

Seidl Petr

Genzyme Europe BV

96

Schůrek Lukáš

PrimeCell a.s.

97

Slovák Jan


98

Smejkal Petr

Ústav analytické chemie AV ČR, v.v.i.

99

Šrubařová Petra, Ing.

MZLU v Brně

100

Šurová Ivana

BioTest s.r.o.

101

Tesaříková Zuzana, Bc.

MZLU Brno

102

Tichá Olga

Fakultní nemocnice u svaté Anny

103

Tomanová Eva, Mgr.

CzechInvest

104

Tomko Jaroslav, Ing.

ZINCHEM, a.s.

105

Ungmanová Lenka, Ing.

Merck spol. s r.o.

106

Weisz Filip

MZLU v Brně

107

Zábský Jan

BioTest s.r.o.

108

Zimová Hana, Bc.


15

www.gate2biotech.cz • www.hospimedica.cz

main partner

2008/10

organisation

How to Create and Grow a Successful Biotechnology Cluster

Recommend Documents